KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.

Youyi Fong, Adrian B McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, An Vandebosch, Mathieu Le Gars, Griet A Van Roey, Christopher R Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Obrimpong Amoa-Awua, Manjula Basappa, Britta Flach, Bob C Lin, Christopher Moore, Mursal Naisan, Muhammed Naqvi, Sandeep Narpala, Sarah O'Connell, Allen Mueller, Leo Serebryannyy, Mike Castro, Jennifer Wang, Christos J Petropoulos, Alex Luedtke, Ollivier Hyrien, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W P van der Laan, Nima S Hejazi, Avi Kenny, Marco Carone, Daniel N Wolfe, Jerald Sadoff, Glenda E Gray, Beatriz Grinsztejn, Paul A Goepfert, Susan J Little, Leonardo Paiva de Sousa, Rebone Maboa, April K Randhawa, Michele P Andrasik, Jenny Hendriks, Carla Truyers, Frank Struyf, Hanneke Schuitemaker, Macaya Douoguih, James G Kublin, Lawrence Corey, Kathleen M Neuzil, Lindsay N Carpp, Dean Follmann, Peter B Gilbert, Richard A Koup, Ruben O Donis, Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team, and the United States Government (USG)/CoVPN Biostatistics Team

Nat Microbiol 7(12) 1996-2010

PMID36357712
PMCIDPMC10166187
DOI10.1038/s41564-022-01262-1
发表日期2022-11-10
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Measuring immune correlates of disease acquisition and protection in the context of a clinical trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing antibody measurements 4 weeks post vaccination as correlates of risk of moderate to severe-critical COVID-19 through 83 d post vaccination in the phase 3, double-blind placebo-controlled phase of ENSEMBLE, an international randomized efficacy trial of a single dose of Ad26.COV2.S. We also evaluated correlates of protection in the trial cohort. Of the three antibody immune markers we measured, we found most support for 50% inhibitory dilution (ID50) neutralizing antibody titre as a correlate of risk and of protection. The outcome hazard ratio was 0.49 (95% confidence interval 0.29, 0.81; P = 0.006) per 10-fold increase in ID50; vaccine efficacy was 60% (43%, 72%) at non-quantifiable ID50 (<2.7 IU50 ml-1) and increased to 89% (78%, 96%) at ID50 = 96.3 IU50 ml-1. Comparison of the vaccine efficacy by ID50 titre curves for ENSEMBLE-US, the COVE trial of the mRNA-1273 vaccine and the COV002-UK trial of the AZD1222 vaccine supported the ID50 titre as a correlate of protection across trials and vaccine types.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。